Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

Boehringer Ingelheim and Microsoft have entered into a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.

Explore retatrutide peptide quality control, including batch testing and supplier documentation checks for laboratory research.

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.

Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

The FDA has granted approval for Cosette’s Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease.

Sanofi has signed a global licensing and strategic collaboration agreement with ScionxBio to develop long-acting mRNA therapies using the TERA platform.

The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.